(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/008099 A2

(51) International Patent Classification[7]: G01N

(21) International Application Number:
PCT/US2003/021590

(22) International Filing Date: 11 July 2003 (11.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/396,290	15 July 2002 (15.07.2002)	US
60/480,043	20 June 2003 (20.06.2003)	US

(71) Applicants *(for all designated States except US)*: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, CA 94080 (US). **F. HOFFMANN - LA ROCHE AG** [CH/CH]; 124 Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **KOLL, Hans** [DE/DE]; Blütenanger 45, 85247 Oberroth (DE). **BOSSENMAIER, Birgit** [DE/DE]; Horst-Wolfram-Geissler-Weg 10, 82229 Seefeld (DE). **MÜLLER, Hans-Joachim** [DE/DE]; Ruhe am Bach 5 b, 82377 Penzberg (DE). **SLIWKOWSKI, Mark, X.** [US/US]; 42 Oak Creek Lane, San Carlos, CA 94070 (US). **KELSEY, Stephen, Michael** [GB/US]; 360 14th Street, Montara, CA 94037 (US).

(74) Agent: **DREGER, Ginger, R.**; Heller, Ehrman, White & McAuliffe LLP, 275 Middlefield Road, Menlo Park, CA 94025 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO,

[Continued on next page]

(54) Title: METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES



(57) Abstract: Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.

WO 2004/008099 A2

RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

(48) Date of publication of this corrected version:

17 February 2005

(15) Information about Correction:

see PCT Gazette No. 07/2005 of 17 February 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.